GlassScriptPhysician profile
Biren P Shah
NPI 1740280114
$16,067.98
in general payments reported to CMS, 2019-2025
29 companies · $278 in 2025
The $278 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $4,126 · 2021: $405 · 2022: $436 · 2023: $451 · 2024: $228 · 2025: $278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $958.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $957.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acessa Health INC. | $13,620.10 | 2019-2020 | |
| Abbvie INC. | $540.23 | 2019-2022 | |
| Hologic Sales and Service, LLC | $463.50 | 2019-2025 | Acessa Provu System, Coolseal Generator, Myosure Tissue Removal Device |
| Sumitomo Pharma America, INC. | $217.93 | 2023-2025 | Myfembree |
| Astellas Pharma US INC | $145.48 | 2023-2025 | Veozah, Myrbetriq |
| Lupin INC. | $141.30 | 2019-2020 | |
| Aspira Women'S Health INC | $115.09 | 2019-2022 | |
| Amgen INC. | $105.83 | 2019-2021 | |
| Gynesonics, INC. | $81.23 | 2023-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Scynexis, INC. | $76.17 | 2022 | |
| Avion Pharmaceuticals | $72.25 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $54.93 | 2024 | Exparel |
| Lsi Solutions INC | $47.64 | 2019 | |
| Myovant Sciences INC. | $46.47 | 2022 | |
| Boston Scientific Corporation | $44.98 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $38.81 | 2023-2025 | Advincula Delineator Uterine Manipulator, Paragard T 380a |
| Innovation Technologies INC | $35.14 | 2022 | |
| Amag Pharmaceuticals, INC. | $30.85 | 2019 | |
| Mimedx Group, INC. | $22.62 | 2025 | |
| Organon LLC | $21.98 | 2023 | Nexplanon |
| Aesculap, INC. | $21.98 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.04 | 2025 | |
| Axonics, INC. | $19.34 | 2022 | |
| Biogen, INC. | $18.33 | 2025 | Zurzuvae |
| Vertical Pharmaceuticals, LLC | $14.56 | 2019 | |
| Coloplast Corp | $14.22 | 2020 | |
| Allergan, INC. | $13.83 | 2019 | |
| Exeltis, USA INC. | $11.66 | 2020 | |
| Dysis Medical, INC. | $11.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Biren Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.